L'ONUSIDA salue le lancement du lénacapavir pour la prévention du VIH en Afrique du Sud

6 juin 2026

Rapporté par l'IA

L'ONUSIDA a salué le déploiement du lénacapavir en Afrique du Sud comme une étape marquante dans la prévention du VIH. Ce médicament injectable est désormais disponible dans 360 établissements de santé publique répartis dans six provinces. Le produit a également été ajouté à la liste nationale des médicaments essentiels.

L'Afrique du Sud a lancé le programme de prévention du VIH par le lénacapavir le 6 juin 2026. L'ONUSIDA a qualifié cette avancée de réalisation historique pour le pays. L'injectable est actuellement disponible dans 360 établissements de santé publique dans six provinces. Les autorités ont ajouté le médicament à la liste des médicaments essentiels de l'Afrique du Sud. L'ONUSIDA a souligné que ce déploiement constitue une mesure importante pour élargir l'accès à des options efficaces de prévention du VIH.

Articles connexes

A volunteer receiving a needle-free vaccine in a lab with AI-designed virus models in the background.

AI-designed “pan-sarbecovirus” vaccine candidate reports early safety and immune-response signals in first human trial

5 juin 2026 Rapporté par l'IA Image générée par IA Vérifié par des faits

A needle-free, DNA-based vaccine candidate designed using machine-learning methods has completed a first-in-human Phase 1 study in the UK, with researchers reporting it was well tolerated and induced immune responses against multiple viruses in the sarbecovirus group, which includes SARS-CoV, SARS-CoV-2 and related bat coronaviruses.

US Pepfar cuts continue to threaten lenacapavir rollout in South Africa

A new NGO report warns that lingering effects of 2025 US Pepfar funding cuts are undermining South Africa's rollout of the six-monthly HIV prevention injection lenacapavir, despite recent US funding restoration efforts and initial shipments. Community infrastructure losses hinder uptake among high-risk groups, even as rollout begins late May.

New HIV pill simplifies treatment for complex cases

1 juin 2026 Rapporté par l'IA

A new combination pill containing bictegravir and lenacapavir shows promise for people with HIV who require complex regimens. The phase three ARTISTRY 1 study found it performed as well as existing multi-pill options. Experts note its impact in South Africa will likely remain limited.

Politique

Ramaphosa says NHI key to bridging public-private healthcare gap

Asie

Nadda chairs meeting on Ebola preparedness

Amérique

Fiocruz starts full national production of tacrolimus for transplants

Study confirms tenth HIV cure case via stem cell transplant

A study published on Monday in Nature Microbiology confirms long-term HIV remission in the «Oslo patient», a 62-year-old man treated for myelodysplasia via stem cell transplant from his brother carrying the CCR5 Delta 32 mutation. He has been off antiretrovirals for four years with no detectable virus. This brings the total to ten patients deemed cured this way.

lundi 01 juin 2026 23h11

L'ONUSIDA salue le lancement du lénacapavir pour la prévention du VIH en Afrique du Sud

Articles connexes

AI-designed “pan-sarbecovirus” vaccine candidate reports early safety and immune-response signals in first human trial

US Pepfar cuts continue to threaten lenacapavir rollout in South Africa

New HIV pill simplifies treatment for complex cases

Ramaphosa says NHI key to bridging public-private healthcare gap

Nadda chairs meeting on Ebola preparedness

Fiocruz starts full national production of tacrolimus for transplants

Study confirms tenth HIV cure case via stem cell transplant

South africa rolls out unprecedented foot and mouth disease vaccination drive

South Africa assesses low risk from new Ebola outbreak

CAR-T cell therapy shows early promise for HIV control

Axel Kicillof announces boost in medication delivery in Buenos Aires

Deputy president highlights TB progress on World TB Day

Ce site utilise des cookies